Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

References

• ZietmanALThe effect of androgen deprivation and radiation therapy on an androgensensitive murine tumor: an in vitro and in vivo studyCancer J Sci Am1997331369072305
   PubMed Web of Science ®Google Scholar
• BollaMLong-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trialLancet200236010310612126818
   PubMed Web of Science ®Google Scholar
• BollaMImproved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelinN Engl J Med19973372953009233866
   PubMed Web of Science ®Google Scholar
• D’AmicoAV6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trialJAMA200429282182715315996
   PubMed Web of Science ®Google Scholar
• DenhamJWShort-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Grou 96–01 randomised controlled trialLancet Oncol2005684185016257791
   PubMed Web of Science ®Google Scholar
• GranforsTCombined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized studyJ Urol1998159203020349598512
   PubMed Web of Science ®Google Scholar
• LaverdiereJThe efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2–T3 prostate cancerJ Urol20041711137114014767287
   PubMed Web of Science ®Google Scholar
• PilepichMVPhase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85–31J Clin Oncol199715101310219060541
   PubMed Web of Science ®Google Scholar
• PilepichMVAndrogen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology GroupUrology1995456166237716842
   PubMed Web of Science ®Google Scholar
• PilepichMVPhase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostateInt J Radiat Oncol Biol Phys2001501243125211483335
   PubMed Web of Science ®Google Scholar
• PilepichMVAndrogen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31Int J Radiat Oncol Biol Phys2005611285129015817329
   PubMed Web of Science ®Google Scholar
• RoachM3rdFour prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trialsInt J Radiat Oncol Biol Phys20004760961510837943
   PubMed Web of Science ®Google Scholar
• RoachM3rdPredicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trialsInt J Radiat Oncol Biol Phys20004761762710837944
   PubMed Web of Science ®Google Scholar
• D’AmicoAV6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trialJAMA20042927821715315996
   PubMed Web of Science ®Google Scholar
• AndroustosGJohn Hunter (1728–1793): fondateur de la chirugie scientifique etpercurseur de l’urologicProg Urol19988108710969894276
   PubMedGoogle Scholar
• WhiteJWThe results of double castration in hyper-trophy of the prostateAnn Surg18952213
   PubMedGoogle Scholar
• HugginsCStudies on prostate cancer: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostateCancer Res19401293
   Google Scholar
• HugginsCStudies in prostatic cancerArch Surg194143209223
   Google Scholar
• BrawerMKThe evolution of hormonal therapy for prostatic carcinomaRev Urol20013S11116986002
   PubMedGoogle Scholar
• SandowJPharmacological studies on androgen suppression in therapy of prostate carcinomaAm J Clin Oncol198811S6S103291602
   PubMedGoogle Scholar
• DebruyneFMJGonadotropin-releasing hormone antagonist in the management of prostate cancerRev Urol20046S253216985933
   PubMedGoogle Scholar
• LoweFCIndications for use of ketoconazole in management of metastatic prostate canerUrology1990365415452247927
   PubMed Web of Science ®Google Scholar
• IversenPNonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and functionBJU Int200187475611121992
   PubMed Web of Science ®Google Scholar
• SchallyAVIsolation and properties of the FSH and LH-releasing hormoneBiochem Biophys Res Commun19714339394930860
   PubMed Web of Science ®Google Scholar
• FujinoMSynthetic analogs of lutenizing hormone releasing hormone (LH-RH) substituted in position 6 and 10Biochem Biophys Res Commun1974604064134608231
   PubMed Web of Science ®Google Scholar
• ChrispPLeuprorelin: a review of its pharmacology and therapeutic use in prostatic disordersDrugs Aging199114875091794035
   PubMedGoogle Scholar
• MonahanMWSynthetic analogues of the hypothalamic lutenizing hormone releasing factor with increased agonist or antagonist propertiesBiochemistry197312461646204589943
   PubMed Web of Science ®Google Scholar
• TolisGTumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonistsProc Natl Acad Sci U S A198279165816626461861
   PubMed Web of Science ®Google Scholar
• SantenRJEvaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostateUrology1985252 Suppl5357
   PubMed Web of Science ®Google Scholar
• AkazaHLong-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study GroupJpn J Clin Oncol1992221771841518166
   PubMed Web of Science ®Google Scholar
• AbouelfadelZLeuprorelin depot injection: patient considerations in the management of prostatic cancerTher Clin Risk Manag2008451352618728847
   PubMedGoogle Scholar
• TunnUWSafety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in EuropeProstate Cancer Prostatic Dis200912838719030021
   PubMed Web of Science ®Google Scholar
• PeritiPClinical pharmacokinetics of depot leuprorelinClin Pharmacokinet20024148550412083977
   PubMed Web of Science ®Google Scholar
• SharifiRTherapeutic effects of leuprorelin microspheres in prostate cancerAdv Drug Deliv Rev19972812113610837568
   PubMed Web of Science ®Google Scholar
• FowlerJEEvaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancerUrology20005563964210792069
   PubMed Web of Science ®Google Scholar
• FowlerJESafety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancerJ Urol200016473073410953135
   PubMed Web of Science ®Google Scholar
• Eligard.com [homepage on the Internet]Bridgewater, New Jersey [updated 2008 February; cited 2009 April 15]. Available from: www.eligard.com
   Google Scholar
• CrawfordEDA 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol200617553353616406989
   PubMed Web of Science ®Google Scholar
• SennelloLTSingle-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administrationJ Pharm Sci1986751581603083092
   PubMed Web of Science ®Google Scholar
• OefeleinMGFailure to achieve castrate levels of testosterone during lutenizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithmJ Urol200016472672910953134
   PubMed Web of Science ®Google Scholar
• MillikanRUpdate of the NCCN guidelines for the treatment of prostate cancerOncology1997111801939430189
   PubMedGoogle Scholar
• ZlottaARExpert opinion on optimal testosterone control in prostate cancerEur Urol Suppl200543741
   Web of Science ®Google Scholar
• McLeodDA phase 3 multicenter open-label randomized trial of abarelix versus leuprolide acetate in men with prostsate cancerUrology20015875676111711355
   PubMed Web of Science ®Google Scholar
• FontanaD3-month formulation of goserelin acetate (‘Zoladex’ 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trialUrol Int20037031632012740498
   PubMed Web of Science ®Google Scholar
• SardosyMFEndocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancerBJU Int19998380180610368200
   PubMed Web of Science ®Google Scholar
• SharifiRLeuprolide Study GroupSerum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of depot leuprolide acetate for advanced prostate cancerJ Urol20021681001100412187208
   PubMed Web of Science ®Google Scholar
• KhanMSAn evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostateUrol Int19986033409519419
   PubMed Web of Science ®Google Scholar
• Perez-MarrenoRA six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerClin Ther2002241902191412501882
   PubMed Web of Science ®Google Scholar
• ChuFMA clinical study of 22.5 mg La-2550: a new subcutaneous depot delivery system for leuprolide aceate for the treatment of prostate cancerJ Urol20021681199120312187267
   PubMed Web of Science ®Google Scholar
• SartorOAn eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancerUrology2003623192312893343
   PubMed Web of Science ®Google Scholar
• RavivarapuHBParameters affecting the efficacy of a sustained release polymeric implant of leuprolideInt J Pharmacol2000194181191
   Web of Science ®Google Scholar
• PathakASDetermining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective studyJ Urol20071772132213517509298
   PubMed Web of Science ®Google Scholar
• GreilSEfficacy over time of LHRH analogs in the treatment of PCa-a prospective analysis using serum testosterone to determine dosing intervalsUrology20097363163419110301
   PubMed Web of Science ®Google Scholar
• GulleyJLKinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancerJ Urol20081801432143718710748
   PubMed Web of Science ®Google Scholar
• SharifiRLeuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancerUrology1998512712769495710
   PubMed Web of Science ®Google Scholar
• TunnUWComparison of LH-RH analogue 1-month and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancerUrol Int Suppl199860916
   PubMed Web of Science ®Google Scholar